DCC HEALTHCARE acquired by INVESTCorporate

Pfizer has finalized the acquisition of Metsera, an operation designed to fundamentally transform the group’s Internal Medicine portfolio and secure a leading foothold in the obesity treatment sector. The strategic rationale for this transaction centers on a "pipeline-transformation" play, merging the target's highly differentiated clinical-stage obesity candidates with the group's global development and commercial infrastructure. This fusion effectively creates a specialized powerhouse in the cardiometabolic arena, providing the organization with a suite of weekly and monthly injectable therapies, alongside oral alternatives, to address the maturing needs of a global patient base

Ottobock successfully completed its Initial Public Offering on the Frankfurt Stock Exchange, marking the largest German IPO of 2025. The shares were priced at €66.00, with the first trading price reaching €72.00 (a 9% premium). At the issue price, the market capitalization stood at €4.2 billion, rising to €4.6 billion upon listing. The strategic rationale for the IPO was to raise gross proceeds to deleverage the balance sheet and accelerate investments in "future technologies," such as AI-integrated bionics and exoskeleton research

CapVest Partners agreed to acquire a controlling majority stake in Stada from Bain Capital and Cinven. This deal serves as an alternative to a planned IPO in Frankfurt, which was shelved due to market volatility. Under the agreement, the previous owners (Bain and Cinven) will retain a significant minority stake to benefit from future upside. CapVest intends to support the management team's strategy of international expansion and further consolidation in the fragmented consumer health market. Canson Capital Partners is also expected to co-invest alongside CapVest

Proteor has orchestrated a secondary Owner Buy-Out (OBO Bis). The transaction allows Ardian Growth to exit its minority position, which it held since the primary OBO in 2021, realizing a return of approximately 3x money. The founding Archambeaud family remains the majority shareholder, continuing its 4th-generation leadership. The strategic rationale for this new round is to consolidate Proteor’s industrial activity and fund future international acquisitions, building on the successful integration of Freedom Innovations in the USA

The deal represents a strategic investment by LGT Capital Partners, Montagu, and Astorg in Nemera, a leading global manufacturer of complex drug delivery devices. The transaction is expected to support Nemera's future growth plans, including enhancing its portfolio, expanding manufacturing capacity, and investing in innovation and operational excellence to meet rising global demand. The investment is closely aligned with the firms' focus on being leading global providers of capital solutions for private equity fund managers and their portfolio companies

Lauxera Capital Partners has successfully finalized the divestment of its minority equity stake in UK-based OrganOx to Japanese medical giant Terumo, marking the first historical exit for the medtech-focused growth investor. Since its initial entry into OrganOx’s capital by leading a £25 million funding round in 2023, followed by co-leading a $142 million expansion round in February 2025 alongside HealthQuest, Lauxera has successfully driven a five-fold increase in OrganOx’s revenue base within a two-year holding period

The French medical diagnostics giant Sebia welcomes a new heavyweight investor, Warburg Pincus, into its capital. This transaction, valuing the company at over EUR5 billion, sees the partial exit of minority shareholders CDPQ and ICG. The current majority owners, CVC Capital Partners and Tethys Invest (the Bettencourt-Meyers family office), retain a significant stake and will continue to back the company alongside Warburg Pincus. This new consortium aims to support Sebia's expansion in the US and Asian markets and fund potential acquisitions in the IVD space

BC Partners, a leading European investment firm, and Bpifrance have finalized the landmark acquisition of Biogaran from Servier. As a cornerstone of the French pharmaceutical industry and the domestic leader in generic medicines, Biogaran enters a new phase of independence. The transaction was completed on January 30, 2026, following regulatory approvals and strict oversight regarding foreign investment in France.

Advanced Instruments has finalized the acquisition of Nova Biomedical, a maneuver designed to fundamentally reshape the global biopharma analytics and clinical diagnostic landscape. The strategic rationale for this transaction centers on a "portfolio-convergence" play, merging the target's industry-leading point-of-care and bioprocess monitoring technology with the group’s established leadership in osmometry and specialized lab analytics. This fusion effectively creates a specialized powerhouse in the life sciences tools sector, providing the organization with an end-to-end suite of analytical hardware required for modern drug development and patient monitoring

In May 2025, Ottobock, through its subsidiary Vigo, acquired Matton OrthoMedi as part of its strategy to consolidate the European technical orthopedics market. The primary objective of this acquisition is to strengthen Ottobock's network of care centers in Western Europe by integrating a well-established local player in Belgium. Matton OrthoMedi brings a established network of locations in Ghent, Bruges, and Brussels, as well as over 30 years of expertise in orthopedic care and custom device manufacturing, catering to patients with complex mobility needs